Incyte Announces Executive Leadership Appointments

Contributed by: Business Wire

Logo

Tags

Biotechnology

Pharmaceutical

Health

Incyte

More Like This

Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025

Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress

Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Chad Swanson, Ph.D., Chief Development Officer, Prothena (Photo: Business Wire)

Prothena Announces Leadership Team Updates

Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025

Anaveon appoints Biotech Leader Thaminda Ramanayake as Chief Executive Officer

Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting

Incyte Announces New Data from across its Oncology Portfolio to be Presented at ESMO Congress 2023